Explore how the optimization of Interactive Response Technologies (IRT) settings relieved the burden of managing global supply needs for a CRO customer and clinical sponsor.

Guido D’Agostino, Head of Global Procurement at Chiesi, and Stefan Dürr, Senior Director of Product Management and Client Delivery at IQVIA IRT, delve into their achievements in sustainability.

Gain insight into why pharma companies generally seek IRT vendor relationships to ensure high-quality builds that meet their needs and avoid the potential pitfalls associated with RTSM.

This article takes a more in-depth look at Sections 5.0.5: ‘Risk Communication’ and 5.0.6: ‘Risk Review.’ in ICH-GCP E6 R2 to show how the implementation of RBQM can reduce issues and achieve holistic trial oversight in today’s complex decentralized trials.

This paper highlights why the industry is moving towards RBQM and how sponsors can build a scalable approach that protects trial participants, upholds study integrity, and increases operational efficiencies.

Explore how digital health technologies offer a data-driven solution to cytokine release syndrome (CRS) monitoring, reducing inpatient care requirements while ensuring patient safety.

With so many moving parts in a clinical trial, why worry about the technology that is supposed to help manage it? In this webinar, explore five actionable and necessary strategies to leverage RTSM to simplify clinical trial operations.

Explore why engaging randomization and trial supply management (RTSM) services early in study startup can help protect clinical trials and expose substantial efficiencies, effectively baking in practices that help streamline supply chains.

Since the FDA is now encouraging creativity in trial designs, it is important for all stakeholders to adapt processes to follow the science and ultimately bring medicines to patients, faster. This white paper addresses the complexities that come with these trial designs, and how randomization and trial supply management (RTSM) solutions are critical to run flexible, robust, and quality-driven trials.

Global standards and AI are transforming clinical research. Learn why mastering ICH E6(R3) and risk-based compliance is critical for data integrity and future success.

Artificial intelligence is reshaping regulatory medical writing by accelerating document development while maintaining compliance and scientific rigor, creating faster, regulator-ready submissions without compromising quality.

AI is reshaping clinical trials by accelerating patient recruitment, optimizing protocol design, and improving data quality—driving faster, more efficient, and more inclusive research outcomes.

Managing participant payments in clinical trials is a multifaceted challenge impacting participants, sites, and sponsors alike. Delve into the intricacies and numerous hurdles faced in this process.

Learn about the evolving U.S. clinical trial site market landscape including a detailed analysis of ownership models, market segmentation, and the role of financial investors in acquisitions. 

The effort to build a single home for sites to access their trial systems has demonstrated that the industry is ready to forego competitive discourse to deliver benefits to sites and patients.